Results 211 to 220 of about 113,181 (243)

HBV vaccination and HBV infection induces HBV-specific natural killer cell memory

Gut, 2020
ObjectiveVaccination against hepatitis B virus (HBV) confers protection from subsequent infection through immunological memory that is traditionally considered the domain of the adaptive immune system. This view has been challenged following the identification of antigen-specific memory natural killer cells (mNKs) in mice and non-human primates.
Ratna S Wijaya, Scott A Read, Naomi R Truong, Shuanglin Han, Dishen Chen, Haleh Shahidipour, Nicole L Fewings, Stephen Schibeci, Mahmoud K Azardaryany, Grant P Parnell, David Booth, David van der Poorten, Rita Lin, Jacob George, Mark W Douglas, Golo Ahlenstiel   +15 more
openaire   +3 more sources

Development of anti-HBV agents targeting HBV capsid proteins

RSC Medicinal Chemistry, 2023
>Design and synthesis of anti-hepatitis B virus (HBV) agents: A small anti-HBV compound, Cpd4 (1), was identified by in silico screening. Its structure–activity relationship studies discovered a more potent derivative, TKB-HBV-CA-001 (3b).
Takuya Kobayakawa, Masayuki Amano, Miyuki Nakayama, Kohei Tsuji, Takahiro Ishii, Yutaro Miura, Kouki Shinohara, Kenichi Yamamoto, Masao Matsuoka, Hirokazu Tamamura   +9 more
openaire   +2 more sources

HBV induced carcinogenesis

Journal of Clinical Virology, 2005
Hepatocellular carcinoma (HCC) is one of the rare human neoplasms associated with viral infections. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most important etiological factors of HCC, accounting for more than 70% of cases worldwide. The risk of HCC development is greatly increased in chronic viral carriers exposed to other recognized
Delphine, Cougot, Christine, Neuveut, Marie Annick, Buendia   +2 more
openaire   +2 more sources

The role of HBV-induced autophagy in HBV replication and HBV related-HCC

Life Sciences, 2018
Hepatitis B virus (HBV) is infecting about 364 million people around the world. It can cause various diseases, such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). However, the present anti-viral treatment in clinics is limited; studies for new therapies are highly desired.
Mingjie Xie, Zhenggang Yang, Yanning Liu, Min Zheng   +3 more
openaire   +2 more sources

HBV plus HCV, HCV plus HIV, HBV plus HIV

Current Gastroenterology Reports, 2006
Coinfection of hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV is common due to shared modes of transmission. These coinfections accelerate the course of chronic liver disease and facilitate progression to cirrhosis and hepatocellular carcinoma.
James S, Park, Neeraj, Saraf, Douglas T, Dieterich   +2 more
openaire   +2 more sources

Interpretation of HBV Serologies

Clinics in Liver Disease, 2021
Hepatitis B was discovered by researchers who were investigating jaundice associated with blood transfusions as well as parenterally administered medications. Through trial and error, the HBV was identified. There are specific tests that detect HBV infection, whether it is a previous exposure or active infection. The various HBV serologies are reviewed
Philippe J, Zamor, Ashley M, Lane
openaire   +2 more sources

���������������� ������������ ������ ������ ������ �������������������� ��(HBV)

2005
The study of hepatitis B virus (HBV) kinetics during antiviral therapy contributes to understanding the mechanisms of infection, treatment antiviral effects and treatment failures. HBV DNA kinetics have been poorly characterized in HBeAg-negative chronic hepatitis B (CHB) patients.
openaire   +1 more source

Treatment options in HBV

Journal of Hepatology, 2006
The available evidence on interferon-alpha (IFN) treatment for chronic hepatitis B is sufficient to conclude that in patients with HBeAg positive chronic hepatitis, standard IFN therapy significantly improves clearance of HBeAg (number needed to treat [NNT] = 4), loss of HBV-DNA (NNT = 4) and clearance of HBsAg (NNT = 18).
CRAXI, Antonio, ANTONUCCI G, CAMMA', Calogero   +2 more
openaire   +3 more sources

A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA

Journal of Gastroenterology
Currently, standard treatments for chronic hepatitis B such as nucleos(t)ide analogs (NAs), effectively reduce hepatitis B virus (HBV) loads but rarely result in a functional cure (defined as sustained HBsAg loss). We report the discovery of a novel, 4-pyridone compound, SAG-524, a potent and orally bioavailable small molecule inhibitor of HBV ...
Takehisa Watanabe, Sanae Hayashi, Yan Zhaoyu, Hiroki Inada, Katsuya Nagaoka, Masakuni Tateyama, Yasuhito Tanaka   +6 more
openaire   +2 more sources